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ABSTRACT
In 2014 and 2015, the largest Ebola virus
disease (EVD) outbreak in history affected
large populations across West Africa. The
goal of this report is to provide an update
on the epidemic and review current progress
in the development, evaluation and
deployment of prevention and treatment
strategies for EVD. Relevant information was
identified through a comprehensive literature
search using Medline, PubMed and CINAHL
Complete and using the search terms Ebola,
Ebola virus disease, Ebola hemorrhagic fever,
West Africa outbreak, Ebola transmission,
Ebola symptoms and signs, Ebola diagnosis,
Ebola treatment, vaccines for Ebola and
clinical trials on Ebola. Through 22 July
2015, a total of 27,741 EVD cases and 11,284
deaths were reported from all affected
countries. Several therapeutic agents and
novel vaccines for EVD have been developed
and are now undergoing evaluation.
Concurrent with active case investigation,
contact tracing, surveillance and supportive
care to patients and communities, there has
been rapid progress in the development of
new therapies and vaccines against EVD.
Continued focus on strengthening clinical
and public health infrastructure will have
direct benefits in controlling the spread of
EVD and will provide a strong foundation for
deployment of new drugs and vaccines to
affected countries when they become
available. The unprecedented West Africa
Ebola outbreak, response measures, and
ensuing drug and vaccine development
suggest that new tools for Ebola control may
be available in the near future.
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INTRODUCTION
Ebola virus (EBOV) derived its name from the
Ebola River in Democratic Republic of Congo
(DRC) (formerly Zaire) where the first Ebola
virus disease (EVD) outbreak was identified in
1976 [1]. Historically, outbreaks of EVD have
been confined to a single country and have
been brought under control by domestic health
agencies working in conjunction with
international organizations such as the World
Health Organization (WHO). However, since
March 2014, West African countries, notably
Guinea, Liberia and Sierra Leon, have
experienced the largest EVD outbreak in their
history [2]. Although the origins of EVD in the
most recent outbreak remain under
investigation, the spread of EBOV occurred
rapidly because of a number of factors
including funeral and burial practices for
decedents [3, 4].
The scope and severity of the EVD outbreak
underscore the urgent need for development
and evaluation of affordable therapeutic and
prophylactic agents that can be made available
for at-risk populations across Africa. Over the
past 17 months, the West Africa EVD outbreak
has provided an important opportunity to
consider use of and evaluate several
therapeutic and prophylactic agents (e.g.,
vaccines) to determine their safety and efficacy
[5, 6].
Review Methods
For this review, we considered published and
unpublished reports related to EBOV and
EVD. We reviewed reports from
peer-reviewed literature published from 1993
through 2015 and cited in several electronic
databases including Medline, PubMed and
CINAHL Complete on ‘‘Ebola,’’ ‘‘Ebola virus
disease,’’ ‘‘Ebola hemorrhagic fever,’’ ‘‘West
Africa outbreak,’’ ‘‘Ebola transmission,’’ ‘‘Ebola
symptoms and signs,’’ ‘‘Ebola diagnosis,’’
‘‘Ebola treatment,’’ ‘‘vaccines for Ebola’’ and
‘‘clinical trials on Ebola’’ (Fig. 1). The gray
literature, health organization websites,
clinical trial registries and corporate websites
were inspected and reviewed to identify
up-to-date information relevant to Ebola.
Studies were included in the proposed
literature review if they (1) were published
in the English language; (2) were full-text
articles; (3) focused on Ebola virus virology,
epidemiology, diagnosis, treatment and
clinical trials on vaccines and treatment; (4)
were published between 1993 and 2015; (5)
were published in peer-reviewed journals. We
excluded studies if they (1) were not full-text
articles; (2) were published before 1993; (3)
were published in non-peer-reviewed
journals. We identified 156 studies for
inclusion in this review. Seventy-one studies
focused on epidemiology, public health
issues, clinical syndrome of EVD and
diagnostic tools. An additional 89 studies
provided information on therapeutic and
vaccine clinical trials that target EBOV. Data
were abstracted from published and
unpublished reports to describe disease
patterns, burden of illness in past and
present outbreaks as well as effects of
investigational therapies and vaccines. This
article is based on previously conducted
studies and does not involve any new
studies of human or animal subjects
performed by any of the authors.
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Virology
Filoviruses (family Filoviridae) are enveloped,
linear, non-segmented, negative and
single-stranded RNA viruses belonging to the
order Mononegavirales. Ebolavirus and
Marburgvirus are the two genera of filoviruses
that have been identified to cause severe
disease in humans [7, 8]. Within the genus
Ebolavirus, five viruses are recognized (EBOV,
Sudan virus, Reston virus, Taı¨ Forest virus and
Bundibugyo virus) with each representing a
different virus species (Zaire ebolavirus, Sudan
ebolavirus, Reston ebolavirus, Taı¨ Forest ebolavirus
and Bundibugyo ebolavirus). In contrast, the
genus Marburgvirus contains a single virus
species (Marburg marburgvirus), and two
distinct viruses have been recognized,
Marburg virus and Ravn virus [9–11]. In 2011,
a novel third genus of filovirus named
Cuevavirus was reported from post-mortem
tissues of bats collected in 2002 in Northern
Spain [12]. Cuevavirus has not been grown in
cell culture, and its pathogenic potential for
humans remains unknown. To date, a single
species (Lloviu cuevavirus) has been approved by
the International Committee on Taxonomy of
Viruses (ICTV) [9].
Fig. 1 Flowchart for the literature search
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The current West Africa outbreak is caused
by Zaire ebolavirus, which shows 97% identity to
EBOV strains from the DRC and Gabon [13].
The genome of EBOV contains seven genes
named nucleoprotein (NP), virion protein (VP)
24, VP30, VP35, VP40, glycoprotein (GP) and L
protein [14]. Each one of these genes encodes a
corresponding structural protein. The main
proteins targeted by experimental treatments
are the NP, VP35, GP, VP24 and L protein. NP is
the main component of the viral nucleocapsid
and encapsulates the viral RNA. VP35 is also
part of the nucleocapsid and, together with
VP24, interferes with innate host immunity.
The surface GP is responsible for the attachment
to the cellular receptor and viral entry. L protein
is the RNA-dependent RNA polymerase [15–20].
Early reports suggest that the EBOV variant
of the 2014–2015 West Africa outbreak
accumulated mutations that may have an
impact on the performance of certain
diagnostic tests or even on the efficacy of
several experimental treatments. Gire et al.
analyzed the genetic sequence of 99 EBOV
genomes from 78 patients in the four most
affected countries of the West African region
[16]. They found significant rates of genomic
variation in EBOV in the current outbreak when
compared with the EBOV genomic sequence in
the 2004 Ebola outbreak in the DRC. Although
the impact of these mutations on the diagnostic
tests and experimental therapeutics has not yet
been proven, some mutations exist in viral
genes that are targeted by primers of some
reverse transcription-polymerase chain reaction
(RT-PCR) protocols [21], as well as mutations in
the binding sites of target proteins of some
experimental treatments such as anti-GP
monoclonal antibodies [22]. In 2015, Hoenen
and colleagues studied full-length sequences of
two clusters of EBOV imported from Mali and
found that the gene sequence of EBOV has
remained stable during the current Ebola
outbreak [23].
Epidemiology and Outbreaks
Ebola viruses have been responsible for 33
outbreaks in six African countries [2].
Historically, the outbreaks have affected
hundreds of individuals where effective
control of outbreaks was achieved primarily
through isolation of cases and contact tracing.
However, from 2000, EVD outbreaks have been
recognized almost every year with substantial
variation in morbidity and case-fatality rates
ranging from 24% to 81% [24]. High
case-fatality rates have been associated with
the Zaire and Sudan subtypes [25]. In the
ongoing Ebola outbreak, the overall
case-fatality rate has been estimated to be
approximately 41% for West Africa and other
affected countries [26]. Most recently, although
the number of cases has declined substantially
(Fig. 2), EVD cases continue to be reported
(please see the supplemental table for details)
in Guinea, Liberia and Sierra Leone with WHO
Ebola situation reports noting weekly cases in
July 2015 [27]. In July 2015, situation report
statistics from the WHO suggest that the
greatest current burden of EVD is found in
Guinea (n = 43) and Sierra Leone (n = 31).
Liberia reported the lowest EVD case number
(n = 3) in the week of 29 June through 5 July
[27].
The search for the natural reservoir host of
EBOV has been a matter of investigation during
the last decades. There is mounting evidence
that a number of mammal species may harbor
and transmit the virus. Several bat species (i.e.,
Epomops franqueti, Hypsignathus monstrosus and
Myonycteris torquata) have been found to carry
filoviruses [28–35]. In addition, EBOV viral RNA
and/or antibodies have been found in these
368 Infect Dis Ther (2015) 4:365–390
animals [30, 32, 34], and Marburg virus has




Humans may acquire the disease by close
contact with biological fluids from infected
animals or patients. During the acute phase of
illness, EBOV has been detected in a variety of
body fluids including breast milk, saliva, semen,
stool, sweat, tears and urine [36–40].
Nevertheless, the EBOV viral load by organ has
not been extensively studied although EBOV
has been detected in the semen of survivors up
to 3 months following onset of symptoms [41,
42]. EBOV has been isolated from urine and
from aqueous humor samples 9 days and
9 weeks, respectively, after the virus was
cleared from plasma [37, 43].
The clinical presentation of the current West
Africa outbreak is, in general, similar to that
described in prior EBOV epidemics. The
incubation period for person-to-person
transmitted EVD typically ranges from 8 to
Fig. 2 Map of the West African region showing the
number of days passed since the last case reported to the
World Health Organization. Last updated 24 June 2015.
Reprinted from the Ebola Response Roadmap. Map of
West Africa showing when the last cases of Ebola occurred.
24 June 2015. http://www.cdc.gov/vhf/ebola/outbreaks/
2014-west-africa/distribution-map.html. Copyright 2015
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11 days, but cases have been reported with
incubation periods as short as 2 and as long as
21 days. Shorter incubation periods may be
observed following direct inoculation of virus
through injection with contaminated needles
[44, 45]. Patients often present to health care
providers within 1 week of symptom onset [21,
46]. In the early clinical phase of EVD, patients
manifest signs and symptoms that mimic
common tropical illnesses (e.g., dengue,
malaria, typhoid fever and other viral
infections) [16, 47, 48]. The onset of the
disease includes nonspecific clinical signs such
as fever, headache, extreme asthenia, arthralgia,
myalgia and back pain. Progressive
gastrointestinal (GI) symptoms often develop
within 3 to 5 days of symptom onset [44,
49–51]. GI manifestations include abdominal
pain, anorexia, nausea, vomiting and diarrhea,
which lead to profound electrolyte imbalance,
intravascular volume depletion and shock.
Conjunctival injection, rash, hiccups,
respiratory and neurologic findings have been
also reported. Bleeding is a late clinical sign that
occurs only in less than 20% of patients with
EVD [44]. However, if hemorrhage occurrs, a
dismal outcome can be predicted. In 2015, Barry
et al. studied the correlation between the
occurrence of symptoms and death in 89
patients with EVD. These investigators found
hemorrhage, shortness of breath and myalgia
were independently associated with death [52].
Clinical deterioration may progress rapidly
resulting in death within 7 to 10 days.
Vulnerable populations include children
under the age of 5 years, pregnant women and
the elderly [49]. EVD in these groups also
include unspecific symptoms in the clinical
presentation. Qin et al. did not find
differences related to mortality between
patients less than 10 years of age and others
between 11 to 20 years old, but they found that
patients aged\30 years had a much lower case
fatality rate than those aged [30 years [22/38
(57.9%) and 20/23 (87.0%), respectively, with
p = 0.0175] and that survivors attended Ebola
Treatment Centers earlier after the onset of
symptoms [53]. No evidence suggests that
pregnant women are more susceptible to
EBOV infection than the general population.
However, they might be at increased risk of
severe illness and fetal loss. Although no large
series are available, the fetal outcome is
generally fatal.
Immune suppression and a systemic
inflammatory response due to the release of
cytokines and other proinflammatory mediators
lead to the impairment of vascular, coagulation
and immune systems [54]. This can result in
multiorgan failure and shock resembling a
septic shock syndrome. Massive fluid losses
due to intense vomiting and profuse diarrhea
can result in dehydration and hypovolemic
shock [49]. Severe lymphopenia as well as
significant deterioration of renal and liver
functions, which may be reflected in high
blood urea nitrogen, serum creatinine and
hepatic enzymes (i.e., aminotransferases and
alkaline phosphatase), can occur [21, 55, 56].
Since EBOV is a contagious pathogen, the
WHO and Centers for Disease Control (CDC)
have issued recommendations for proper
handling of biological specimens from
suspected cases of EVD [57, 58]. Extreme
caution should take place at all stages (i.e.,
specimen acquisition, transport, processing and
testing) of specimen processing, and
appropriate biosafety laboratory procedures
must be used when handling biological
specimens from patients with suspected EVD.
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DIAGNOSIS OF EBOLA VIRUS
DISEASE
Rapid and reliable diagnosis of EVD is essential
for appropriate and effective patient
management, hospital or health center
infection prevention and control, and
optimization of use of healthcare resources
[59]. Diagnosis of suspected cases is confirmed
by EBOV-specific laboratory tests that detect the
EBOV genome (e.g., RT-PCR) or measurement of
the EBOV antigen or specific antibodies [42]. In
the past 10 months, the West Africa EVD
outbreak has stimulated the development of
new diagnostic tests, including rapid antigen
detection tests and nucleic acid detection (NAT)
tests such as loop-mediated isothermal
amplification (LAMP) assays [60, 61].
Enzyme-Linked Immunosorbent Assay
Antigen Detection
Prior to 2000, antigen detection methods [e.g.,
enzyme-linked immunosorbent assay (ELISA)]
were the gold standard for EBOV detection in
some outbreaks [62]. In the acute phase of EVD,
ELISA has a relatively high sensitivity (93%), but
EBOV antigen levels decline as disease
progresses, rendering lower sensitivity for
antigen detection 1–2 weeks following
symptom onset [41, 63]. Several other antigen
detections tests are currently under evaluation
and may be deployed in the near future to
complement RT-PCR testing [60]. ELISA testing
has been largely replaced by RT-PCR, which
permits more rapid detection and can now be
deployed in mobile (portable) testing platforms
in outbreak settings [64].
Antibody Detection
Detection of IgM antibodies against EBOV is
performed by ELISA in the first week after the
onset of symptoms with a peak of IgM levels
occurring in the 2nd week of illness [41, 48, 62].
IgM antibodies are cleared at variable rates from
1 to 6 months after illness onset [41]. Data
showed that serology can be highly specific for
the EVD diagnosis but less sensitive in the
intensive care unit setting. Hence, antibody
testing may be less clinically useful in the
diagnosis and management of critically ill EVD
patients [49]. Although IgG antibodies appear
soon after the IgM and may persist for years
[41], a substantial number of EVD patients have
died before they develop an IgG antibody
response [48].
Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
Nucleic acid tests (NATs), particularly RT-PCR,
are regarded as the gold standard for EVD
diagnosis, in part because of their high
sensitivity and specificity in detecting the
Ebola viral genome. This is generally
accomplished by international mobile teams
deployed in institutions such as the European
Mobile Laboratory or CDC. RT-PCR is a rapid
and highly sensitive nucleic acid amplification
test to detect EBOV nucleic acid [65]. The
sensitivity and specificity of RT-PCR are
approximately 100% and 97%, respectively
[63]. Within the first 3 days of illness,
molecular assays may not detect the viral
genome, which may lead to false-negative
results. Therefore, RT-PCR should be repeated
in subsequent samples [49, 66]. To minimize
false-negative results, proper sampling,
collection, storage or transportation, and a
proper RT-PCR technique have to be
implemented to avoid cross-contamination
[49, 54]. Quantitative RT-PCR has been
developed and could possibly be used to
monitor the viral load since data suggest high
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viremia might be associated with unfavorable
outcomes and death [21, 46]. For those patients
receiving experimental treatments, EBOV viral
load monitoring could be useful to assess
treatment response [48].
The WHO recommends that specimens
tested by RT-PCR outside of the designated
EBOV diagnostic laboratories should be sent to
a WHO Collaborating Center for confirmatory
testing. These collaborating centers include the
Institut Pasteur de Lyon (France) and the
Bernhard-Nocht Institute for Tropical
Medicine (Germany), National Microbiology
Laboratory Public Health Agency of Canada
(Canada), Centre International de Recherches
Me´dicales de Franceville (Gabon), Kenya
Medical Research Institute (Kenya), Institut
Pasteur de Dakar (Senegal), National Institute
for Communicable Diseases (South Africa),
Uganda Virus Research Institute (Uganda) and
the Centers for Disease Control and Prevention
(USA) [58].
Portable PCR techniques are currently under
development and featured to be readily
deployed in the field for rapid diagnosis
(10–30 min). These techniques are anticipated
to have minimum biosafety requirements and
do not require laboratory infrastructure [67].
Portable PCR techniques can play a more
effective role in disease surveillance and
control including Ebola outbreaks and other
infectious diseases [68].
Other Diagnostic Approaches
Next-generation sequencing (NGS) techniques
provide powerful methods that allow screening
for a wide number of pathogens and provide
complete genome data. NGS methods may be
useful to detect Ebola virus in situations where
the clinical index of suspicion is not high or
where there is low urgency for diagnostic
information. However, once an Ebola outbreak
is suspected, faster methods such as specific
real-time RT-PCR protocols are preferred for
screening of suspected patients. In this setting,
NGS techniques are valuable tools for
full-length genomic analysis, identification of
viral variants and detection of possible
emerging viral mutations.
The development of rapid point-of-care
diagnostic tests has accelerated in the face of
the West Africa outbreak. These tests may
provide viable options for Ebola diagnosis
particularly in field settings. The results of
rapid Ebola test evaluations suggest that assays
have reached high sensitivity (100%) and
specificity (90%) [69–71]. Although rapid
diagnostic tests are promising tools, they are
not yet used in daily practice, and real-time




The provision of clinical supportive care is now
a cornerstone of EVD patient management,
which includes rehydration, nutrition,
analgesics and blood transfusion when
appropriate, though no clear evidence proves
their effectiveness [21]. A key aspect of
supportive care is the maintenance of
intravascular volume with oral rehydration
solution (ORS) or intravenous fluids that
provide appropriate electrolyte replacement.
The use of antiemetics and antidiarrheal
agents may also be important for patients with
persistent vomiting and diarrhea [21, 49, 50].
Prophylactic antimicrobial agents with
intravenous third-generation cephalosporins
(e.g., ceftriaxone and cefotaxime) may be
administered when secondary bacterial
372 Infect Dis Ther (2015) 4:365–390
infections and septicemia are suspected [72].
Parasitic coinfections (e.g., malaria) can occur,
and appropriate diagnosis and treatment for
these diseases are recommended whenever
feasible [73].
Targeted Antivirals Compounds/Drugs
The high case-fatality rate associated with
advanced EVD highlights the need for
therapeutic agents that reduce, inhibit or
eliminate EBOV from infected tissues and
organs. An available effective treatment would
be necessary for outbreak management in order
to improve the prognosis of infected patients as
well as to reduce the viral load and therefore the
risk of new infections. Among experimental
antiviral treatments, several potential
therapeutic agents have shown promise
(Table 1), and their mechanisms of action are
different [6].
Small Interfering RNA Agents
One formulation (i.e., TKM-Ebola) of small
interfering RNAs (siRNAs) that target EBOV is
encapsulated in lipid nanoparticles to facilitate
cellular delivery. SiRNAs cause cleavage in the
messenger RNAs, which subsequently prevent
EBOV production of three key viral proteins.
Early animal studies have demonstrated that
TKM-Ebola prevents infection in animals
challenged with a lethal dose of EBOV [74,
75]. TKM-Ebola was administered by
intramuscular injection to two groups of
macaques 30 min following receipt of a lethal
dose of EBOV. One group was treated with
TKM-Ebola on days 1, 3 and 5 post-exposure,
and the other group was treated post-exposure
every day for 6 consecutive days. The first
regimen provided 66% protection, and the
second gave 100% protection [74]. Although
the drug was tested on quite a few patients with
EVD in Europe and the US with most of them
surviving the disease, but because these patients
received other experimental therapies including
hyperimmunoglobulin serum and proper
supportive care in medically advanced
facilities, clear evidence of effectiveness and
safety in humans is lacking [76]. In 2014,
TKM-Ebola entered phase I clinical trials to
evaluate the safety and pharmacokinetics
among volunteer participants. However,
clinical manifestations of inflammatory
mediator (cytokine) appeared in participants
who were treated with TKM-Ebola [77, 78].
Given the observed adverse events, the US
Food and Drug Administration (FDA) placed a
partial clinical hold on the trial. Since dose
modifications were introduced in the
TKM-Ebola trial, the FDA has allowed
continuation of the study for patients with
EVD. Currently, one TKM-Ebola phase I trial is
active and being undertaken in San Antonio,
Texas, and another TKM-Ebola phase I trial has
been terminated by Tekmira, Inc., aiming to
reformulate the investigational therapeutic
(Table 1). Additionally, Tekmira, Inc., started a
phase II trial on TKM-Ebola in Guinea.
However, on 19 June 2015, Tekmira, Inc.,
released a letter stating that the phase II trial
closed enrollment prior to completion.
Preliminary data from the incomplete phase II
trial indicated no therapeutic benefit was
achieved from the use of TKM-Ebola. A full
report from this trial is pending [79].
Other siRNA-based agents are in
development, including phosphorodiamidate
morpholino oligomers [80–82]. These agents
include AVI-6002 and AVI-6003, which are
composed of multiple oligomers with
positively charged piperazine residues located
along the oligomeric backbone. In 2011, a
phase I randomized, double-blind,
placebo-controlled, single-dose, dose-escalation
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trial to assess the safety, tolerability and
pharmacokinetics of AVI-6002 in healthy adult
subjects was completed (ClinicalTrials.gov
Identifier: NCT01353027). In a similar trial,
the same group of investigators evaluated the
use of AVI-6003 against Marburg virus as a
post-exposure therapy (ClinicalTrials.gov
Identifier: NCT01353040). In these trials, both
AVI-6002 and AVI-6003 were well tolerated by
healthy human volunteers [80].
Favipiravir (T-705)
Favipirarvir is a nucleotide analog and viral RNA
polymerase inhibitor with a wide range of
antiviral effects against numerous negative- or
positive-strand RNA viruses [83–88]. Initially,
favipiravir was developed to treat influenza
viruses, and a phase III clinical trial was
completed in which favipiravir was tested on
several thousands of people and proven to be
safe and effective [84]. Recently, favipiravir has
also shown efficacy against EBOV in vitro and
in vivo in a mouse model [89]. Two
independent animal studies have
demonstrated that treatment with favipiravir
resulted in rapid viral clearance and led to
survival of all animals infected with EBOV
through intranasal inoculation [89, 90]. A
phase II clinical trial to evaluate the efficacy of
favipiravir against EBOV in 225 patients with an
Table 1 Overview of Ebola virus therapeutics in development
Agent Manufacturer Stage of evaluation ClinicalTrials.gov
identiﬁer number








Institut National de la Sante´ Et de la
Recherche Me´dicale, France




Chimerix (Durham, NC) Phase II (withdrawn prior
recruitment)
NCT02271347
JK-05 [152] Sihuan Pharmaceutical
Holdings Group Ltd and Academy of
Military Medical Sciences (Beijing, China)
Animal studies completed; now
considered for use in emergency
situations for army only
N/A
BCX4430 [95] BioCryst Pharmaceuticals
Inc., Durham, NC
Phase I ongoing NCT02319772





None identiﬁed Animal studies completed N/A
ZMapp [132, 135,
155, 156]
National Institutes of Health Clinical
Center (National Institute of Allergy and
Infectious Diseases (NIAID)
Phase I/II ongoing NCT02363322
FDA US Food and Drug Administration, N/A not applicable
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EVD trial has been completed in Guinea [91,
92]. The investigators of this trial are in the
midst of data analysis with results forthcoming
in the near future. The French drug safety
agency approved compassionate use of
favipiravir in patients with EVD [93], and the
drug was used to treat a French nurse who
contracted EBOV while a volunteer with
Me´decins Sans Frontie`res (MSF) in Liberia [94].
BCX4430
BCX4430 is a novel adenosine analog that
inhibits viral RNA polymerase activity, which
results in termination of RNA synthesis. This
compound has shown promising results and
confers protection to EBOV-challenged mice
and monkeys, even when administered
following challenge with filoviruses such as
Marburg and Ravn viruses [95]. Furthermore,
BCX4430 has demonstrated broad-spectrum
antiviral activity against many viruses,
including bunyaviruses, arenaviruses,
paramyxoviruses, coronaviruses and
flaviviruses [95]. From a safety perspective, it is
worth noting that BCX4430 may have an
acceptable side effect profile as it does not
incorporate into human RNA or DNA. In vitro
activity against EBOV has been shown for
BCX4430, but no data in humans have been
obtained to date. Currently, the timing of
treatment for drugs such as BCX4430 has not
been established, although early treatment in
high-risk or potentially EBOV-exposed
individuals may be an option [96]. Oral
administration of BCX4430 may be feasible,
although the pharmacokinetic data suggest that
the intramuscular route may provide more
favorable therapeutic levels [95].
Brincidofovir (CMX001)
Brincidofovir is a prodrug of cidofovir and a
fairly recent oral nucleotide analog that
prevents viral replication by inhibiting DNA
polymerase [97]. Brincidofovir has shown
broad- spectrum antiviral activity against DNA
viruses such as herpes viruses and adenovirus
and is currently in a phase III clinical trial
against cytomegalovirus and adenovirus [98,
99]. Although the exact mechanism of action
for brincidofovir in EVD is not yet well
understood, brincidofovir may interfere with
RNA polymerase of EBOV. The US FDA has put
brincidofovir on fast-track approval for
treatment of EVD based on in vitro data alone
[99]. A phase II open-label multicenter study to
assess the safety and efficacy of brincidofovir
against EBOV in humans has been withdrawn
prior recruitment (ClinicalTrials.gov Identifier:
NCT02271347). As a result of the dramatic
decline in the number of new cases in Liberia
in the month of January 2015 where the trial
was first initiated, Chimerix, Inc., decided to
discontinue the trial with no further discussions
[100].
Other Small Molecules and Compounds
There are a number of known agents and newly
identified compounds that have shown
anti-EBOV activity. For example, Compound 7
is a benzodiazepine derivative that also prevents
EBOV entry into the host cells [101].
Preliminary analysis suggests that Compound
7 binds near a hydrophobic pocket near the
EBOV GP1 and GP2 interface. Analysis of this
compound suggests that it may have activity
against several filoviruses including EBOV [101].
No animal or human trials have been reported
to date.
NSC 62914 is a small molecule, which has an
antioxidant property, and was found to inhibit
many viruses, including EBOV, Lassa virus,
Venezuelan equine encephalitis virus and Rift
Valley fever virus [102]. This compound, a
reactive oxygen species, has shown in vitro
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activity against EBOV as well as some evidence
in the EBOV mouse model for protection
against lethal EBOV infection at a treatment
dose of 2 mg/kg/injection (higher doses did not
improve survival in the mouse model). Further
studies of this or related compounds in mouse
and other animal models may be warranted to
elucidate their role in the treatment of EBOV
and other filovirus infections.
Of additional interest are compounds that
have been proven to be effective in preventing
the entry of filoviruses, including EBOV, into
host cells [103]. LJ-001 binds to lipid membranes
and prevents virus-cell fusion across awide range
of viruses. Additional research will be needed to
understand how such compounds can be
optimally formulated to maximize both the
safety and pharmacologic activity in vivo.
FGI-103, FGI-104, and FGI-106 are a group of
broad-spectrumantiviral agents that inhibit viral
replication in a dose-dependent manner among
multiple and genetically distinct viruses
including EBOV, bunyaviruses, dengue virus,
HIV and hepatitis C virus [104]. Using a mouse
model, Aman et al. found that FGI-106 yields a
protection after a challenge with a lethal dose of
EBOV. Aman and colleagues showed that
protection was also found when FGI-106 was
administered in a prophylactic fashion. In
related studies, FGI-103 and FGI-104 are also
small molecules that inhibit filovirus infection
and are found to protect EBOV- or
Marburg-infected mice, although their
mechanism of actions are unclear [105, 106].
In 2011, a novel finding by Carette et al.
showed that EBOV cell entry requires the endo/
lysosomal Niemann-Pick C1 cholesterol
transporter protein (NPC1) [107]. NPC1 is a
fundamental component to facilitate EBOV
glycoprotein host membrane fusion. Cells that
are defective in the NPC1 are resistant to
infection by EBOV. In addition, inhibition of
NPC1 can also disrupt the release of EBOV from
the intracellular vesicular compartment.
Benzylpiperazine adamantane diamides are
NPC1 inhibitors that have been found to
interfere with EBOV binding to NPC1 on the
host cells and subsequently inhibit EBOV entry
and infection [108]. Clomiphene and
toremifene, which are selective estrogen
receptor modulators, have recently been
discovered to have NPC1 inhibitor activity and
act as potential inhibitors of EBOV [109, 110].
Some anti-arrhythmic therapeutics such as
amiodarone and verapamil also have been
identified as potent NPC1 inhibitors of the
entry of the EBOV [109, 111]. Their
effectiveness has been proven in cell culture,
and some trial work on amiodarone is under
preparation now in West Africa [112].
Immunotherapy
Convalescent Whole Blood and Plasma
Historically, convalescent whole blood (CWB)
and plasma (sometimes referred to as
convalescent sera) and hyperimmune serum
(HS) have been employed for diseases that
may be severe or result in serious
consequences and for which there is no safe
and effective drug or vaccine. In 1995, passive
immunotherapy or convalescent immune
plasma was used clinically to treat patients
with EVD in the outbreak of Kikwit, DRC
[113]. In this study, eight patients were given
the blood of convalescent patients where 7/8
(87.5%) of patients survived the disease. To
date, however, there are no definitive human
clinical trial data showing that CWB or CP are
effective in reducing either the severity or
duration of EVD [114]. In animal studies
reported in 2007, Jahrling et al. used whole
blood from non-human primates (NHPs)
surviving EVOV infection to treat other
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animals, which challenged with lethal dose of
EBOV [115]. Researchers in this study
concluded that there was no beneficial effect
following the administration of
convalescent-phase whole blood to
EBOV-infected NHPs.
In contrast, Dye and colleagues used
multiple doses of concentrated polyclonal IgG
antibody from NHPs that had survived filovirus
infection to treat Marburg virus-infected NHPs
[116]. Results of this study demonstrated very
effective post-exposure IgG treatment where
none of the experimental NHPs showed signs
of the disease or detectable viremia.
Furthermore, surviving NHPs were
re-challenged with Marburg virus, and all
survived the re-challenge, indicating that they
were able to produce Marburg virus-specific IgM
antibodies to fight virus replication. Subsequent
evaluations were conducted to demonstrate
Marburg virus or EBOV-infected NHPs could
survive the disease even if IgG treatment was
delayed 2 days post infection. Successfully, both
Marburg- and EBOV-infected animals survived
the disease, though one out of three infected
animals showed mild disease yet fully recovered
afterwards. Promising results of these studies
demonstrate the effectiveness of post-exposure
antibody treatments and represent an option
for EVD therapies for human use.
In the current West Africa Ebola outbreak,
convalescent-phase plasma administration for
treatment of EVD is undergoing an open label,
phase II/III nonrandomized trial among 130–200
patients in Guinea [117]. For use of CP or CWB,
the WHO has provided guidance to improve the
safety of product development as well as safety
for patients who receive these products
[118–120]. Convalescent sera-based therapy
may cause some toxicity related problems, such
as transmission of undetected pathogen(s) and
transfusion reactions. A recent case report from
treating a Spanish nurse who had contracted
EBOV during her care to a patient with EVD in
Spain shed some light on the issue of using
experimental therapeutics including CP [121].
The infected nurse had received convalescent
sera from two survivors of EVD, high-dose
favipiravir and other supportive care treatment.
On the 10th day of clinical disease, the nurse
developed clinical signs and symptoms
suggestive of post-transfusion acute lung injury,
which was managed conservatively without the
need of supportive mechanical ventilation.
Although purified IgG can lower these risks,
lot-to-lot variation remains a potential problem.
Previous experience also highlights the risk of
antibody-dependent enhancement of EBOV
infection [122]. To address challenges with
convalescent sera-based therapies, researchers
have developed highly purified polyclonal
antibodies or monoclonal antibodies that
specifically target neutralizing glycoprotein
epitopes of the EBOV envelope [123]. The
long-term prospects for use of CP also require
clinical laboratory infrastructure for the
collection and testing of CWB or CP from
recovered Ebola patients in order to ensure
administration of safe blood products in the
context of an EVD outbreak.
Monoclonal Antibodies (ZMapp)
Natural infection with EBOV induces antibodies
directed against the EBOV envelope
transmembrane glycoprotein, which is
essential to virus attachment, fusion and entry
into host cells. In the past several years, a
number of studies have developed and
characterized monoclonal antibodies directed
against epitopes of EBOV antigens. Within the
genus Ebolavirus, there are five antigenically
distinct viruses that generate antibodies that
may or may not cross-react with other Ebola
species. In 2015, Hernandez and colleagues used
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a panel of mouse monoclonal antibodies to
extensively study cross-reactivity, avidity and
viral GP epitope binding [124]. This research
team identified four monoclonal cross-reactive
antibodies that bind to GPs of five Ebolavirus
species. These findings suggest that monoclonal
antibodies directed against the five species of
Ebolavirus may be useful for both clinical
diagnosis and therapy.
In earlier efforts, investigators developed a
cocktail of antibodies from two groupings
(MB-003 and ZMab), each containing three
unique monoclonal antibodies. MB-003 was
composed of three humanized chimeric
monoclonal antibodies (c13C6, c6D8 and
h13F6) [123], while ZMAb was composed of
three other different monoclonal antibodies
(m1H3, m2G4 and m4G7) [125]. By direct and
specific reaction with EBOV GP, these
antibodies are thought to provide passive
immunity against the virus by directly reacting
with the EBOV envelope glycoprotein
[126–128]. In one study, ZMAb demonstrated
100% efficacy in NHPs where four of four
cynomolgus macaques survived EBOV
infection when given the first dose of ZMAb
24-h after exposure followed by two additional
doses 3 days apart. However, when the first dose
was delayed and given at 48 h after a lethal dose
of EBOV exposure, 50% of the monkeys fully
recovered [129]. A potent humoral and
cell-mediated immune response was mounted
in all animals recovered from the lethal
challenge of EBOV, and all survived monkeys
fully recovered from a subsequent EBOV
reintroduction [130]. Recent research showed
that treatment with ZMAb can be delayed as
late as 72 h post EBOV exposure when ZMAb is
given in combination with adenovirus vectored
human interferon-a [131]. In 2012, another
group of researchers demonstrated a high
protection rate against EBOV infection among
rhesus macaques when MB-003 monoclonal
antibodies were first administered at 48 h
post-exposure followed by two additional
doses [125]. In this study, MB-003 monoclonal
antibodies protected four of six animals (67%)
against EBOV infection.
In an effort to optimize the monoclonal
antibody cocktail composition to contain the
most potent epitopes for neutralizing
antibodies that may effectively inhibit EBOV
replication and further prolong the
post-exposure treatment window, a group of
researchers conducted an animal study to test
different combinations of monoclonal
antibodies from MB-003 and ZMAb [132].
After several animal experimental trials,
investigators of this study selected ZMapp as
the best monoclonal antibody formulation with
the best protection effect. ZMapp was composed
of one monoclonal antibody from MB-003
(c13C6) and two monoclonal antibodies from
ZMAb (2G4 and 4G7). With this selected
combination of monoclonal antibodies, rhesus
macaques were treated with ZMapp at 5, 8 and
11 days after challenge with EBOV at a lethal
dose of 50 mg/kg per dose. Although animals of
this study exhibited signs and symptoms of EVD
and viral load was detected at 5 days
post-challenge before treatment with ZMapp
was initiated, all animals survived. A follow-up
at 3 weeks post EBOV-exposure demonstrated
an undetectable viral load in all animals [132].
This is strong evidence that ZMapp could be
a potential therapeutic modality in humans
even when signs and symptoms of EVD have
manifested. In July 2014, two US healthcare
workers were brought from Liberia to the USA
after being diagnosed with EVD and were
treated with aggressive fluid replacement and
electrolyte correction. Both were given ZMapp
and showed a decline in the level of Ebola
plasma viral load in correlation with clinical
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improvement. Although they improved shortly
after receiving ZMapp, their clinical course
cannot be exclusively attributed to the
monoclonal antibodies, as other measures of
care could have and probably did play a major
role to the clinical improvement [133].
Clinical use of ZMapp maybe practically
challenging given the limited supplies of the
drug since the three monoclonal antibodies of
ZMapp are currently extracted from the plant
Nicotiana benthamiana [132]. A new scalable
transient expression technology (magnifection)
could overcome future ZMapp shortages. Using
magnifection, 0.5 g of ZMapp can be extracted
and purified from 1 kg N. benthamiana leaf
biomass [134]. While this product holds
promise, a major hurdle in its future utility is to
manufacture large quantities of eachmonoclonal
antibody from plants in a way that ensures
sustained high yield of monoclonal antibodies
at reasonable cost [135]. To overcome potential
rate-limiting steps in large-scale production,
ZMapp can be manufactured using Chinese
hamster ovary (CHO) cells.
In February 2015, a partnership between
Liberia and the US National Institute of
Allergy and Infectious Diseases (NIAID)
initiated clinical trials to evaluate the safety
and efficacy of ZMapp in the treatment of EVD.
The original study is designed to have two-arm
comparison with each arm including 100
people; one arm will receive the standard of
care and the other arm the experimental ZMapp
treatment [136]. While randomized controlled
trials are planned, with declining EVD case
loads, a modification of the original trial
designs may be required to evaluate the safety
and efficacy of ZMapp.
Nonspecific Agents
Many potential therapeutic agents have shown
some post-exposure efficacy in alleviating
symptoms of EVD with direct antiviral action.
Despite the high safety profile compared with
other newly discovered antivirals, these agents
cannot be used alone because of their low
efficacy, but they can be used in combination
with other treatments available including
supportive care measures.
Interferon: Since its discovery in 1950,
interferon has not been widely used because of
the associated adverse events [123]. The
potential use of interferons in the treatment of
EVD is rooted in the evidence that EBOV
interferes with functions of type I interferons
[137–139]. Previous pre-clinical research
showed that exogenous interferon-a or
interferon-b could delay the occurrence of
viremia or prolong survival time, but could
not save animals from death [140, 141].
Recombinant Nematode Anticoagulant
Protein c2 (rNAPc2) and Recombinant Human
Activated Protein c (rhAPC): EBOV infections
cause coagulation diathesis as one of the
important pathogenesis factors for the
development of EVD [142]. The two originally
licensed anticoagulant drugs available are
rNAPc2 and rhAPC. These drugs have
demonstrated in previous studies partial
protection of NHPs from ZEBOV lethal
challenge, with associated survival rates of
33% and 18%, respectively [143, 144]. In
December 2014, the US FDA granted the
manufacturer (ARCA Biopharma, Westminster,
CO) orphan drug status for rNAPc2 as a
potential post-exposure treatment for EVD
[145].
Ebola Vaccine Candidates
Ebola vaccine development was initiated in
the 1980s. A number of vaccine candidates
have been tested in rodents and NHPs,
including inactivated virus, DNA vaccines,
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virus-like particles (VLPs) and vaccines based
on recombinant viral vectors [146]. Animal
models have been developed to test the
efficacy of vaccine candidates, including
mice, guinea pigs and other NHPs. Rodent
models do not always predict vaccine efficacy
in NHPs and employ EBOV-adapted strains.
NHPs (usually rhesus and cynomolgus
macaque) can be infected with non-adapted
strains and best mimic disease progression in
humans, and therefore they are considered the
‘‘reference’’ animal model for vaccine studies
[147]. Differences can also be found in the
EBOV antigens included in the vaccines.
While the main antigen for vaccine
development has been the EBOV surface GP,
some candidates such as the VLPs-based
vaccine have also included the NP and the
VP40 matrix protein. A novel approach
includes a replication-deficient recombinant
EBOV lacking the gene encoding for VP30,
an essential transcription factor that plays a
fundamental role in viral replication [148],
and has been recently shown to protect NHPs
against EBOV [149]. This vaccine differs from
other EBOV advanced vaccine platforms in
that all viral proteins and the viral RNA are
presented to the immune system, which
might contribute to protective immune
responses.
With the global impact of the West Africa
EVD outbreak, research and development for
new Ebola vaccine candidates has been
stimulated, though no licensed vaccine is
currently available. In the past year,
investment in vaccine candidates has led to
initiation of phase I, II and III human clinical
trials (Table 2). More advanced vaccine
candidates are based on viral vectors such as
adenoviruses and vesicular stomatitis virus
modified to express the EVOB surface GP.
FUTURE DIRECTIONS
Evidence identified through the cumulative
experience across multiple EVD outbreaks
since the 1970s strongly suggests that EVD
can be considered a zoonotic disease that has
emerged and spread as human contact with
wild animal species has increased. Additional
ecological, epidemiologic and clinical disease
surveillance will continue to be important
throughout Ebola-endemic countries and to
investigate possible triggering factors and
predictors of new future outbreaks. In 2014
and 2015, the rapid evolution of the West
Africa outbreak highlighted the need for
additional research into systems and
technologies that accelerate local, national
and international health organization
responsiveness to containment of EBOV
transmission and epidemics. Multi-disciplinary
team-based research will be extremely
important particularly given the socio-cultural
factors that have fueled and sustained EVD
outbreaks. While new diagnostic tests look
promising in providing more timely and
accurate EBOV detection, there will be a need
for additional research to study optimal
strategies for deploying these diagnostics to
locations where testing is most needed. In the
near future, there is a substantial likelihood
that one or more drugs and vaccines will be
approved for use in the treatment and
prevention of EVD. The availability of new
agents for prevention, acute therapy and
post-exposure prophylaxis will require
additional research to identify and reduce
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barriers to their access, distribution and
administration.
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